DSM Integrated Annual Report 2020

11 Other financial assets

 

 

Loans associates and joint ventures

 

Other participating interests

 

Other receivables

 

Other

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 January 2019

 

2

 

164

 

88

 

9

 

263

 

 

 

 

 

 

 

 

 

 

 

Changes:

 

 

 

 

 

 

 

 

 

 

- Charged to the income statement

 

-

 

-

 

9

 

(2)

 

7

- Acquisitions

 

-

 

-

 

-

 

1

 

1

- Capital payments

 

-

 

23

 

-

 

-

 

23

- Loans granted / prepayments

 

4

 

-

 

9

 

-

 

13

- Repayments

 

(2)

 

-

 

(5)

 

-

 

(7)

- Exchange differences

 

-

 

-

 

1

 

-

 

1

- Transfers

 

(1)

 

(15)

 

3

 

-

 

(13)

- Changes in fair value

 

-

 

(21)

 

-

 

-

 

(21)

- Other

 

-

 

(1)

 

-

 

(1)

 

(2)

Balance at 31 December 2019

 

3

 

150

 

105

 

7

 

265

 

 

 

 

 

 

 

 

 

 

 

Changes:

 

 

 

 

 

 

 

 

 

 

- Charged to the income statement

 

-

 

-

 

-

 

(2)

 

(2)

- Acquisitions

 

-

 

-

 

-

 

4

 

4

- Disposals

 

-

 

(47)

 

-

 

-

 

(47)

- Capital payments

 

-

 

11

 

-

 

-

 

11

- Loans granted / prepayments

 

1

 

-

 

8

 

-

 

9

- Repayments

 

-

 

-

 

(5)

 

4

 

(1)

- Exchange differences

 

-

 

-

 

(10)

 

-

 

(10)

- Transfers

 

-

 

-

 

(7)

 

(4)

 

(11)

- Changes in fair value

 

-

 

106

 

-

 

-

 

106

- Other

 

-

 

(1)

 

(6)

 

-

 

(7)

Balance at 31 December 2020

 

4

 

219

 

85

 

9

 

317

‘Disposals’ includes the divestment of our other participating interest in probiotic company UAS Laboratories, Inc.

‘Changes in fair value’ consists mainly of the value increase of our minority share in Amyris, Inc. (€78 million) and of our share in UAS Laboratories, Inc. prior to divestment (€38 million).